<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03882164</url>
  </required_header>
  <id_info>
    <org_study_id>PoliclinicoUAG-LTU</org_study_id>
    <nct_id>NCT03882164</nct_id>
  </id_info>
  <brief_title>Blood-Bile Ratio Tacrolimus After Liver Transplantation</brief_title>
  <acronym>BBRT</acronym>
  <official_title>Use of Tacrolimus Blood-bile Ratio for the Detection of Early Liver Failure After Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tacrolimus is the most widely used immunosuppressive drug in the prevention of rejection
      after solid organ transplantation. Pharmacokinetic studies in healthy volunteers and in
      transplanted patients have shown that this molecule is rapidly absorbed after oral
      administration (maximum plasma concentration after 1-2 hours), is found in the circulation
      bound mainly to erythrocytes and, after being metabolized by CYP3A4, is eliminated through
      the bile. The importance of the tacrolimus blood dosage is now widely recognized for
      detecting the immunosuppressive capacity reached in the individual patient or the eventual
      overdose of the drug. In the use of Tacrolimus after Liver Transplantation, however, it is
      interesting to note that the biochemical pathway for metabolism and excretion of the drug is
      present in the transplanted organ, the main object of immunological and functional
      surveillance. The excretory capacity of Tacrolimus by the liver through the bile, therefore,
      could be a useful tool for recognizing the early liver failure from a functional point of
      view, before the onset of hepatoecrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective monocentric randomized study comparing two parallel groups:

      liver transplanted patients with early (10 POD) organ rejection (experimental arm); liver
      transplanted patients without early (10 POD) organ rejection (control arm) Primary Objective:
      Evaluation of a correlation between the reduction of Tacrolimus biliary excretion and the
      early liver failure Primary Endpoint: Increase of Tacrolimus blood-bile ratio measured before
      the onset of laboratory hepatonecrosis Secondary Objective: Analysis of the cause of any
      drug-related toxicity Secondary Endpoint: correlation study between drug dosage and biliary
      excretion level in case of blood overdose or clinical evidence of pharmacological toxicity
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Days</target_duration>
  <primary_outcome>
    <measure>Analysis of early liver rejection</measure>
    <time_frame>10 days</time_frame>
    <description>Evaluation of early liver rejection throught creation of a Tacrolimus blood-bile ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of Tacrolimus toxicity</measure>
    <time_frame>10 days</time_frame>
    <description>Evaluation of Tacrolimus toxicity throught blood dosage of the drug</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">55</enrollment>
  <condition>Liver Transplant; Complications</condition>
  <condition>Immunosuppression</condition>
  <condition>Transplant Failure</condition>
  <condition>Transplant; Complication, Rejection</condition>
  <arm_group>
    <arm_group_label>Rejection</arm_group_label>
    <description>Patient undergone liver transplant with diagnosis of rejection within 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-Rejection</arm_group_label>
    <description>Patient undergone liver transplant wothout diagnosis of rejection within 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood-Bile Ratio of Tacrolimus</intervention_name>
    <description>Diagnosis of early transplanted liver dysfunction to adjust Tacrolimus dose adminstered</description>
    <arm_group_label>Rejection</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood; Bile
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergone liver transplant with positioning of Kehr tube
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  History of recent liver transplant (less than 10 days)

          -  Placement of kehr tube in the biliary tract during liver transplant

          -  Immunosuppressive therapy with Tacrolimus

          -  Functioning of kehr tube

        Exclusion Criteria:

          -  Age - Age ≥18 years

          -  History of liver transplant for more than 10 days

          -  Liver transplant without positioning of kehr tube

          -  Immunosuppressive therapy with a drug different from Tacrolimus

          -  No functioning of kehr tube18 years

          -  History of liver transplant for more than 10 days

          -  Liver transplant without positioning of kehr tube

          -  Immunosuppressive therapy with a drug different from Tacrolimus

          -  No functioning of kehr tube
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Marco Maria Pascale</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00167</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 17, 2019</study_first_submitted>
  <study_first_submitted_qc>March 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</investigator_affiliation>
    <investigator_full_name>Dr. Marco Maria Pascale</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>Liver transplant;</keyword>
  <keyword>Immunosuppression;</keyword>
  <keyword>Transplant rejection;</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

